Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-05-26
2008-09-02
Minnifield, N. M. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S234100, C424S247100, C530S300000
Reexamination Certificate
active
07419675
ABSTRACT:
Methods for treating peritoneal adhesions by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a peritoneal adhesion.
REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6261572 (2001-07-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6358917 (2002-03-01), Carruthers et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6447787 (2002-09-01), Gassner et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6623742 (2003-09-01), Voet
patent: 6667041 (2003-12-01), Schmidt
patent: 6787517 (2004-09-01), Gil et al.
patent: 2002/0177545 (2002-11-01), Donovan
patent: 2003/0224019 (2003-12-01), O'Brien
patent: 2004/0009180 (2004-01-01), Donovan
patent: 2005/0123567 (2005-06-01), First
patent: 198 52 981 (1998-11-01), None
patent: WO 96/33273 (1996-04-01), None
patent: WO 98/07864 (1997-08-01), None
patent: WO 99/17806 (1998-10-01), None
patent: WO 00/57897 (1999-03-01), None
patent: WO 00/10598 (1999-08-01), None
patent: WO 00/15245 (1999-09-01), None
patent: WO 00/74703 (2000-05-01), None
patent: WO 01/21213 (2000-09-01), None
patent: WO 03/011333 (2002-07-01), None
Webster's II New Riverside University Dictionary, The Riverside Publishing Company, 1984.
U.S. Appl. No. 10/814,764, filed Mar. 31, 2004, First.
U.S. Appl. No. 10/817,036, filed Apr. 2, 2004, First.
Aoki K., et al,Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing,Cephalalgia Sep. 2003;23(7):649.
Asahina A., et al.,Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide: relevance to functional effects,Proc Natl Acad Sci U S A. Aug. 29, 1995;92(18):8323-7.
Bhutani M.S., et al.,Botulinum toxin injection in achalasia before myotomy,Am J Gastroenterol Jun. 1998;93(6):1012.
Bigalke H., et al.,Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture,Brain Research 360;318-324:1985.
Bigalke H., et al.,Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord,Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981.
Binz T. et al.,The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins,J Biological Chemistry 265(16);9153-9158:1990.
Boyd,Mov Disord,10(3):376:1995 (pancreatic islet B cells contains at least SNAP-25 and synaptobrevin).
Brem, H., et al,Placebo-Controlled Trial of Safety and Efficacy of Intraoperative Controlled Delivery by Biodegradable Polymers of Chemotherapy for Recurrent Gliomas,Lancet 345;1008-1012:1995.
Bushara K.,Botulinum toxin and rhinorrhea,Otolaryngol Head Neck Surg 1996;114(3):507.
Childers et al. (2002), American Journal of Physical Medicine & Rehabilitation, 81:751-759.
Chuang, et al., Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats, J Urol Apr. 2004;171(4 Suppl).
Doggweiler R., et al.,Botulinum toxin type A causes diffuse and highly selective atrophy of rat prostate,Neurourol Urodyn 1998;17(4):363.
Eaker E. Y., et al.,Untoward effects of esophageal botulinum toxin injection in the treatment of achalasia,Dig Dis Sci Apr. 1997;42(4):724-7 1012.
Ellis, H., The clinical significance of adhesions: focus on intestinal obstruction.European Journal of Surgery,Suppl (577), 5-9 (1997).
Fung L. K. et al.,Pharmacokinetics of Interstitial Delivery of Carmustine 4-Hydroperoxycyclophosphamide and Paclitaxel From a Biodegradable Polymer Implant in the Monkey Brain,Cancer Research 58;672-684:1998.
Goldman (2000), Aesthetic Plastic Surgery Jul.-Aug. 24(4):280-282.
Gonelle-Gispert,Biochem J 1;339 (pt 1):159-65:1999.
Gordon J.M., et al.,Prospective study of esophageal botulinum toxin injection in high-risk achalasia patients,Am J Gastroenterol Oct. 1997;92(10):1812-7 1012.
Habermann E., et al.,Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain,J Neurochem 51(2);522-527:1988.
Habermann E.,Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate,Experientia 44;224-226:1988.
Habermann,Naunyn-Schmiedeberg's Arch. Pharmacol.1974; 281, 47-56.
Harrison's Principles of Internal Medicine(1998), edited by Anthony Fauci et al., 14th edition, published by McGraw Hill.
Hokfelt T.,Neuropeptides in perspective : The last ten years,Neuron 1991; 7: 867-879.
Hosoi J., et al.,Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide,Nature. May 13, 1993;363(6425):159-63.
Hsieh S., et al.,Skin Innervation and Its Effects on the Epidermis,J Biomed Sci. 1997;4(5):264-268.
Inaba N., et al., Capsaicin-induced calcitonin gene-related peptide release from isolated rat stomach measured with a new chemiluminescent enzyme immunoassay, Jpn J Pharmacol. Nov. 1996;72(3):223-9.
Jankovic J. et al.,Therapy With Botulinum Toxin,Marcel Dekker, Inc., (1994), p. 5 and 150.
Johnson M.,Synaptic glutamate release by postnatal rat serotonergic neurons in microculture,Neuron 1994; 12: 433-442.
Kaneko T., et al.,Immunohistochemical demonstration of glutaminase in catecholaminergic and serotonergic neurons of rat brain,Brian Res. 1990; 507: 141-154.
Kasakov L., et al.,Direct evidence for concomitant release of noradrenaline, adenosine 5″-triphosphate and neuropeptide Υ from sympathetic nerve supplying the guinea-pig vas deferens.J. Auton. Nerv. Syst. 1988; 22: 75-82.
Kupfermann I.,Functional studies of contransmission.Physiol. Rev. 1991; 71: 683-732.
Legat F., et al.,Repeated subinflammatory ultraviolet B irradiation increases substance P and calcitonin gene-related peptide content and augments mustard oil-induced neurogenic inflammation in the skin of rats,Neurosci Lett. 2002 Sep. 6;329(3):309-13.
Lundberg J.,Pharmacology of cotransmission in the autonomic nervous system: Integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide,Pharmacol. Rev. 1996; 48: 113-178.
Menzies, D., et al.,Intestinal obstruction from adhesions—how big is the problem?, Annals of the Royal College of Surgeons,England, 72, 60-63 (1990).
Moyer E et al.,Botulinum Toxin Type B: Experimental and Clinical Experience,being chapter 6, pp. 71-85 of “Therapy With Botulinum Toxin”, edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
Naumann,European J. Neurology6 (Supp 4): S111-S115:1999.
Nicholas A. et al.,Glutamate-like immunoreactivity in medulla oblogata catecholamine/substance P neurons,NeuroReport 1990; 1: 235-238.
Nicholas A., et al.,Serotonin-, Substance P- and Glutamae/Aspartate-like Immunoreactivities in Medullo-Spinal Pathways of Rat and Primate,Neuroscience, vol. 48, No. 3, pp. 545-559.
Pearce, L.B.,Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine,Toxicon 35(9);1373-1412 at 1393.
Ragona,The Laryngoscope109:1344-1346:1999.
Sanchez-Prieto, J., et al.,Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes,Eur J. Biochem 165;675-681:1897.
Schantz, E.J., et al,Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine,Microbiol Rev. 56;80-99:1992.
Senior M.,Botox and the management of pectoral spasm after subpectoral implant insertion,Plastic and Recon Surg, Jul. 2000, 224-225.
Singh,Critical Aspects of Bacterial Protein Toxins,pp. 63-84 (chapter 4) of Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York
Allergan Inc.
Donovan Stephen
Ford Vanessa L.
Minnifield N. M.
Nassif Claude L.
LandOfFree
Method for treating peritoneal adhesions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating peritoneal adhesions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating peritoneal adhesions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3974759